These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 19064956)

  • 1. Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer?
    Takano T; Ota S; Hori A; Seki N; Eguchi K
    J Clin Oncol; 2009 Jan; 27(3):464-5; author reply 465-7. PubMed ID: 19064956
    [No Abstract]   [Full Text] [Related]  

  • 2. Cetuximab in non-small-cell lung cancer.
    Carillio G; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Di Maio M; Daniele G; Giordano P; Bryce J; Normanno N; Rocco G; Perrone F; Morabito A
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):163-75. PubMed ID: 22316364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer.
    Pirker R
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):735-6. PubMed ID: 18997663
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D; Govindan R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab in advanced non-small cell lung cancer.
    Govindan R
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies against EGFR in non-small cell lung cancer.
    Pirker R; Filipits M
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting.
    Langer CJ
    Clin Lung Cancer; 2008 Sep; 9(5):249-51. PubMed ID: 18824445
    [No Abstract]   [Full Text] [Related]  

  • 8. Cetuximab in advanced non-small cell lung cancer.
    Rossi A; Maione P; Gridelli C
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):139-49. PubMed ID: 16806963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer.
    Raez LE; Lopes G; Lilenbaum R
    J Clin Oncol; 2005 Jun; 23(18):4244-5. PubMed ID: 15961783
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role?
    Kalemkerian G
    J Clin Oncol; 2005 Feb; 23(6):1325-6; author reply 1326-7. PubMed ID: 15718337
    [No Abstract]   [Full Text] [Related]  

  • 11. Exploring the future of non-small cell lung cancer treatment.
    Ramalingam S
    Manag Care; 2005 Feb; 14(2 Suppl):9-13; discussion 13-4. PubMed ID: 15776956
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
    Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Jänne PA; Bonomi P
    J Clin Oncol; 2006 Nov; 24(33):5253-8. PubMed ID: 17114658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
    Di Maio M
    Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
    Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
    Eberhard DA; Giaccone G; Johnson BE;
    J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
    J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving role of cetuximab in non-small cell lung cancer.
    Lilenbaum RC
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
    Cohen J; Looney W
    J Natl Cancer Inst; 2010 Aug; 102(15):1207; author reply 1207-10. PubMed ID: 20651322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.